Andecaliximab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Chimeric (mouse/human) |
Target | gelatinase B |
Clinical data | |
Synonyms | GS-5745 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6396H9868N1680O2010S46 |
Molar mass | 143.9 g/mol |
Andecaliximab (GS-5745) (INN[1]) is a humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.[2]
It is currently at Phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma.
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.